KCQs

The positive aspects of Nanosonics is that they have identified and unmet market. This means they don’t have any competitors, which makes it easier for their business to make a profit. It makes it extremely easy to make a profit and expand because they are allowed to put the price at whatever they like because they are not competing with any one for customers at the moment. Every company is not perfect; Nanosonics knows it is not perfect and doesn’t try to misleadingly promote their business or say the company is anything its not. Instead they hold countless meetings and go to countless conventions all over the world so that they can improve their brand. Some of the concerns and risks that are burdening Nanosonics relatively short history is manufacturing capacity, the work environment, intellectual property protection (Nanosonics: 2013, Pg. 35), the introduction of any type of competition, making sure their employees don’t leave to become a competitor, different currencies and the distribution of their products world wide. In the thirteen years that Nanosonics Limited have been operating they have accomplished some huge milestones for example forming Nanosonics Europe GmbH during August 2007 and forming Nanosonics Inc. during June 2011 in America (About us, 2012).  I believe that Nanosonics should not have tried to expand so much and try to establish themselves more in Australia but saying that they have been a big success over seas.  I suggest that Nanosonics should extend their research and design, and manufacture more then just Trophon EPR for example something that cleans hospitals and medical centers that does not mean cleaners have to clean them everyday.

Manufacturing and out look

Manufacturing
Over the past year we have continued our development
as a world class manufacturer of a medical product. We have consolidated our supplier base and strengthened supplier relationships to improve visibility and involvement in materials supply. We continue to develop the capabilities of our production team and continuously improve our processes, quality and yields. Our sales forecast, production planning, purchasing and order fulfilment are now formalised into our Integrated Business Planning processes which, along with the successful implementation of the Manufacturing Resource Planning (MRP) functionality
of our ERP system, provide improved control for the anticipated increase in volumes and complexity.

Outlook
The Company is well positioned for growth and working towards profitability is a focus for 2014. Priorities include:

• Significantly increase market penetration in North America and Europe;
  
• Maximise penetration in our home markets of Australia and New Zealand;
  
• Expand into new Asian markets;
  
• Enhance the range of trophon® EPR accessories; and
  
• Identify the next product opportunity that leverages our platform technology. 
  

Financial Year 2013

Financial Year 2013 has been one of continued growth and maturation for Nanosonics, highlighted by a number of achievements, including:

• Increased sales driven mainly by sales to our key North American market;
  
• Sales growth in the US strongly supported by Nanosonics’ US sales team;
  
• Hiring of a highly experienced team to drive sales in the key European markets;
  
• Forging new and deeper relationships with our major distribution partners;
  
• A significant increase in the number of ultrasound probes that are certified for use with our technology, and broadened our patent portfolio;
  
• Progress towards regulatory approval in new markets including Japan, South Korea and Mexico;
  
• Continued and growing awareness of our technology, with healthcare facilities and regulators who are increasingly alert to the issue of healthcare acquired infection (HAIs); and
  
• Growing evidence of risks associated with TGA/FDA approved liquid disinfection procedures. 
  

The Trophon Product Suite

Simple, safe and cost effective, the trophon® EPR addresses an unmet need for disinfecting intra-cavity ultrasound probes at the point of care. The trophon® EPR is the world’s first fully automated system for disinfecting ultrasound probes, and is compatible with more than 500 models and a dozen manufacturers.
The trophon® EPR stores all disinfection cycle data which can be downloaded on request or during a yearly maintenance service. trophon® EPR is a complete ultrasound probe disinfection system that is fast, easy to use, environmentally-friendly and quality-assured.
Nanosonics has built on the technology of the trophon® EPR by offering an expanded product suite based on customer feedback. The suite aligns trophon® EPR and Nanosonics with the needs of our customers – allowing them to more effectively provide and monitor high-level disinfection procedures. The trophon® EPR product suite expands Nanosonics’ offering in the market and provides additional revenue streams from service contracts and consumables supply.

trophon® PRINTER
The trophon® Printer is a fast, easy-to-use traceability solution for quality system documentation requirements in hospitals and health clinics. The trophon® Printer provides complete and accurate documentation by printing up to four labels per cycle based on operator, site or procedure preferences.

trophon® WALL MOUNT AND CART
Attach the trophon® EPR to the wall for clinics or hospitals with space constraints or make the trophon® EPR mobile to ensure point of care use.

CHEMICAL INDICATORS
Each box of chemical indicators contains 300 indicator tabs which verify successful disinfection when the tab turns from red to yellow. Each box includes a colour assessment chart to cross check the probe has been successfully cleaned.

SONEX HLTM/ NANONEBULANTTM CARTRIDGES
The trophon® EPR runs on cartridges, much like a printer. Changing cartridges is a quick, clean and easy process. Cartridges ensure there is no need for chemical mixing or neutralisation and each cartridge is made from recyclable plastic materials. Empty cartridges can be disposed as standard waste or under recognised disposal procedures. 

Nanosonics Executive team

Nanosonics Limited, Australia

 

Michael Kavanagh BSc MBA (Advanced)

CEO & President

Mr Michael Kavanagh joined Nanosonics as CEO & President effective 21st October 2013. Michael is a highly experienced executive with over 20 years of international commercial experience in the healthcare market having held local, regional and global roles in Medical Devices and Pharmaceutical industries. He holds a BSc Degree from University College Dublin and an MBA (Advanced) from the University of Queensland. Before joining Nanosonics, Michael was Senior Vice President of Global Marketing for the major medical device company Cochlear Limited, a position he held for more than 10 years

Ron Weinberger BSc (Hons), PhD

President Technology Development/Commercialisation

Dr Weinberger joined the Company in August 2004 and was appointed as Executive Director in July 2008. Dr Weinberger was appointed as Chief Executive Officer in May 2011. Dr Weinberger has executive responsibility for the overall leadership of the business and the implementation of its strategies. Since 2004 Dr Weinberger has been in a range of roles leading product development and overseeing manufacturing and operations. He is an intellectual property expert and entrepreneur in the development of novel technologies. Dr Weinberger is co-inventor of several of Nanosonics’ key technology patents which underpin the Company’s platform technology.

McGregor Grant BEc, CA, GAICD

Chief Financial Officer and Company Secretary

Mr Grant joined Nanosonics in April 2011 and is responsible for the overall financial management of the Company and, together with Dr Weinberger, has joint responsibility for investor relations. Mr Grant has over 15 years of business experience in a number of senior roles in the medical device and healthcare industries located in Australia and the United States. Previously Mr Grant worked for Coopers & Lybrand in Australia and Europe.

Gerard Putt BSc

Chief Operations Officer

Mr Putt joined Nanosonics full time in April 2011 after 18 months on the Nanosonics advisory board. Mr Putt has over 12 years’ experience in the Medical Device industry as a leader of development, engineering and production teams at ResMed. As Head of Manufacturing at ResMed, Mr Putt acquired particular experience in the implementation of new products into manufacturing and rapid scaling of production to international market needs. Mr Putt has a strong background in medical device GMP, project management, engineering and entrepreneurial roles in medical, retail and building.

Michael Potas BE (E&C)

Head of Research, Design and Development

Mr Potas joined Nanosonics in August 2006 and has more than 16 years’ experience in the development and commercialisation of new products and technologies. Mr Potas has been instrumental in the research, design & development of the Trophon EPR & associated core intellectual property.

 

       

Vincent Wang BSc, MSc, MBA

Head of Global Support and Services

Mr Wang has over 11 years’ experience in establishing and managing technical support and service repair function in global medical device markets. Before joining Nanosonics in May 2011, Mr Wang worked for Sonova Hearing Healthcare Group as Regional Service Operations Manager and at Cochlear as Regional Technical Service and Repair Manager.

Ruth Cremin MSc

Regulatory Affairs Manager

Ms Cremin joined Nanosonics in June 2011 and has extensive regulatory affairs experience, having worked at Cochlear for over 4 years as a Senior Regulatory Affairs Specialist for the ANZ and Asia Pacific Regions. Prior to this role, Ms Cremin worked at Pfizer Australia as a QA & Regulatory Officer for 4 years and was also a Regulatory Affairs Associate with Bio-Medical Research Ltd in Galway, Ireland.

Jianhe Chen MD, MSc

Quality Assurance Manager

Dr Chen has been with the Company since July 2009. Dr Chen has 9 years’ experience in quality assurance and regulatory affairs in globalised medical device companies, in addition to broad skills and knowledge obtained in clinical practice and medical research. Dr Chen specialised in establishing, developing and maintaining the quality management systems for medical device manufacturers. Dr Chen has held senior leadership roles in various international medical device companies in the past 11 years.

Kirste Courtney BA

Human Resources Manager

Ms Courtney joined Nanosonics in 2009 and has over 14 years of human resources experience having worked in a variety of industry sectors including chartered accounting, media, logistics and banking.

Nanosonics Incorporated, USA

Ronald J Bacskai BSME, MBA (Hons)

President & CEO, Nanosonics Inc.

Mr Bacskai joined Nanosonics in 2010 and is responsible for supporting Nanosonics’ operations in the United States. Mr Bacskai is an experienced executive having worked in multiple industries with a broad technical, marketing and sales, and technology commercialization background. Mr Bacskai has significant experience as President, CEO and board member of several public and private organizations as well as serving on the advisory board of a specialty environmental firm.

board of directors

Maurie Stang

Non-Executive Chairman

Mr Stang was Executive Director and Chairman of Nanosonics Limited from 14 November 2000 to March 2007. He has been Non-Executive Director and Chairman since March 2007. Mr Stang co-founded and is a director of a number of leading healthcare distribution and biotechnology companies. His business activities and experience span the successful commercialisation of intellectual property across global markets. He has a track record of launching and commercialising a broad range of medical and dental devices worldwide.

Ron Weinberger BSc (Hons), PhD

President Technology Development/Commercialisation

Dr Weinberger joined the Company in August 2004 and was appointed as Executive Director in July 2008. Dr Weinberger was appointed as Chief Executive Officer in May 2011. Dr Weinberger has executive responsibility for the overall leadership of the business and the implementation of its strategies. Since 2004 Dr Weinberger has been in a range of roles leading product development and overseeing manufacturing and operations. He is an intellectual property expert and entrepreneur in the development of novel technologies. Dr Weinberger is co-inventor of several of Nanosonics’ key technology patents which underpin the Company’s platform technology.

Richard England FCA, MAICD

Non-Executive Director

Mr England is a chartered accountant and professional non-executive director. He has over 30 years’ experience in accounting and financial services, as well as considerable experience with early stage biotech companies. From 1998 to 2006 Mr England was chairman and a director of Gropep Limited, an Australian biotech company which grew successfully from start-up to be acquired in 2006 by the Danish company Novozymes A/S. From 2003 to 2007, Mr England was a director of ITL Limited, an Australian company which designs and manufactures medical devices and procedure packs for global healthcare markets.

David Fisher BRurSc (Hons), MAppFin, PhD, FFin

Non-Executive Director

Dr Fisher has over 25 years' experience, including substantial operating experience in the biotechnology and healthcare industry in Australia and overseas. He held senior positions with Pharmacia AB in Sweden and was CEO in Australia of Peptech Limited (now Arana Therapeutics Limited). He is Managing Director of Brandon Capital Management Pty Ltd, a venture capital provider and investor in Nanosonics. He is also a director of Australian Biomedical Fund No 1 Ltd, Australian Biomedical Fund No 2 Ltd, and Australian Biotechnology and Healthcare Fund No 3 Ltd.

Michael Kavanagh BSc, MBA (Advanced)

CEO & President

Mr Michael Kavanagh joined Nanosonics as CEO & President effective 21st October 2013.  Michael is a highly experienced executive with over 20 years of international commercial experience in the healthcare market having held local, regional and global roles in Medical Device and Pharmaceutical industries. He holds a BSc Degree from University College Dublin and an MBA (Advanced) from the University of Queensland. Before joining Nanosonics, Michael was Senior Vice President of Global Marketing for the major medical device company Cochlear Limited, a position he held for more than 10 years.

Nanosonics sale teams

Nanosonics Sales Team, USA

Keith Koby BSEET, MBA, CSA

Vice President Sales - North America

Mr. Koby has significant experience in starting up and leading commercial teams in the medical device arena and across the healthcare industry in North America. He has 23 years of sales, service and infection control leadership experience including creating and leading high performance sales teams at GE Healthcare and Medivators a division of Cantel Medical.

Donna Fiorentino BSc, Management and Marketing

Northeast Regional Sales Manager - North America

Ms. Fiorentino joined Nanosonics in 2012 and she is responsible for leading sales in the Northeast Region of the United States.  She has over 20 years of successful sales and new business development experience. She has been a top performer in her various roles and markets throughout her career.

Kevin Markham BSc, Business Administration

Southeast Region Sales Manager - North America

Mr. Markham comes to Nanosonics with 24 years’ of medical experience with a very strong ultrasound background. He spent 17 years with Philips Healthcare in various sales and sales leadership roles. He also spent 4 years with Siemens Healthcare managing a 12 state region for IT and ultrasound solutions and directed his own distribution company.

Lisa Davis MBA, MT(ASCP)

Business Development Manager - North America

Ms. Davis joined Nanosonics Incorporated in April 2011 as the Business Development Manager for North America. She is a versatile global marketing and sales executive with over 28 years’ experience in medical device strategy development and execution within the diagnostics, lab automation and life sciences sectors.

Norman W. Rich BSc, Business Administration

Western Regional Sales Manager - North America

Mr. Rich has a 30 year career of successful medical sales including 24 years selling endoscopy equipment in the Los Angeles area. Mr. Rich consistently ranked at the top tier for competitive conversions. Norm grew a significant market share during this tenure nearing 90%. He achieved the highest level of recognition (Grand Masters Sales Group) during his tenure by converting all large Los Angeles hospitals . Norm achieved equal success in earning high honors for over-achievements during his tenure with Baxter Healthcare.

Ray Beams BSc, Business Administration

South Central Regional Sales Manager - North America

Mr. Beams comes to Nanosonics with 19 years’ experience as medical device sales professional. His well-documented sales achievement in the Medical Device industry demonstartes a record of mastering technology and successful startup adoptions in the healthcare arena. Early in his career he gained valuable experience at Ethicon Endo-Surgery and Baxter Healthcare. Most recently he has been involved in Cardiac Surgery in the fields of atrial fibrillation surgery and heart valve replacement and repair at AtriCure, Inc and Sorin Group, USA. Throughout his career he has consistently ranked in the top tier based on sales results and quota performance.

Thomas F. O’Neill, Jr. Bachelor of Arts, Pre-Law

North Central Regional Sales Manager - North America

Mr. O’Neill has over 30 years of experience, including 26 years selling medical devices throughout the Midwest. He has extensive experience in developing and managing direct sales teams and launching new, innovative products into the US markets. Thomas has a strong background in transitioning distributor relationships into partnerships. He was inducted into the President’s Council and was awarded twice the prestigious International Star Performer Award.

Nanosonics Sales Team, Europe

Bryn Tudor-Owen BSc Anatomy & Physiology / Biochemistry

Country Manager - UK

Mr. Tudor-Owen has 20 years’ experience gained within the medical device industry. Prior to Nanosonics, Bryn held senior positions with both GE Medical Systems and Cardinal Health for more than 14 years before more recently becoming engaged with a German Healthcare SME; driving their UK startup operations. He joined Nanosonics in the autumn of 2012.

Ralf Schmäehling BA (Hons), International Business Administration

Country Manager - Germany

Mr. Schmäehling joined Nanosonics in September 2012. He spent over 12 years in various business, sales and marketing management and leadership functions within blue chip medical device companies. He has a successful track record on strategic and tactical sales execution in the German health care market.

Nanosonics are always trying to improve their company and increase the client base

Conferences Nanosonics Will Be Attending

Conference Nanosonics Will Be Attending	City	Country	Starts	Ends
Hygienesymposium 2013	Ulm	Germany	19 March 2013	22 March 2013
2013 Annual Convention and Preconvention Program American Institute of Ultrasound in Medicine	New York	U.S.A.	06 April 2013	10 April 2013
Centre d'études et de formations hospitalières CEFH	Marseille	France	09 April 2013	11 April 2013
14th World Congress of Ultrasound in Medicine and Biology	Sao Paulo	Brazil	02 May 2013	05 May 2013
Hôpital expo	Paris	France	28 May 2013	30 May 2013
The French society of hospital hygiene SF2H	Paris	France	29 May 2013	31 May 2013
40th Annual Conference Association for professionals in infection control and Epidemiology	Florida	U.S.A.	07 June 2013	10 June 2013
Australasian College for Infection Prevention and Control National conference 2013	Gold Coast	Australia	30 September 2013	02 October 2013
Infection Prevention Society	Excel London	England	30 September 2013	02 October 2013
Deutschen Gesellschaft für Sterilgutversorgung DGSV Kongress 2013	Fulda	Germany	02 October 2013	04 October 2013
23rd World Congress on Ultrasound in Obstetrics and Gynecology WFUMB	Sydney	Australia	06 October 2013	09 October 2013
Euro-Pharmat	Montpellier	France	08 October 2013	10 October 2013
Ultraschall 2013 /Euroson 2013	Stuttgart	Germany	09 October 2013	12 October 2013
Freiburger Hygienekongress	Freiburg	Germany	16 October 2013	18 October 2013
Federation of Infection Societies Conference 2013	Birmingham	England	11 November 2013	13 November 2013
The Radiological Society of North America 99th Scientific Assembly & Annual Meeting	Chicago	U.S.A.	01 December 2013	06 December 2013
British Medical Ultrasound Society	Gateshead	England	09 December 2013	11 December 2013

Where Nanosonics is heading in the future

Nanosonics embraces
ongoing investment in product development

Nanosonics recognises and embraces the requirement for ongoing investment in product development, to encourage company growth. It is fortunate that Nanosonics' platform technology is easily transferable and scalable, which means that it can be integrated into a variety of devices and systems for many markets.

Our product development program covers three key areas:

• Improvements to our current device the Trophon® EPR, including line extensions
• Development of accessory products to enhance our users experience with the Trophon® EPR
• New applications for our platform technology with future product opportunities within the healthcare industry primarily. However, the opportunity exists for expansion into additional markets

Nanosonics' Unique Platform Technology

my company uses a unique platform technology produces a proprietary disinfectant containing sub-micron mist which can be quickly distributed to surfaces requiring disinfection or sterilisation.

At the end of the process, Nanosonics' process breaks down the mist leaving oxygen and water as the primary by-products.

Benefits

Nanosonics' platform technologies have a number of core benefits compared to existing methods, including broad based applications, operator & patient safety and environmentally friendly by-products, low operating temperatures and disinfectant efficacy. Initial applications for our technologies will be designed to address significant challenges currently facing medical and healthcare markets.

A foundation for future product development

Nanosonics' platform technologies provide the foundation for future product development. The company is exploring a number of potential opportunities to adapt its technology into best in class disinfection solutions, designed to meet the needs of target markets.

Protecting our unique platform technology

Seems my company is the only company in its field they have to make sure no one can steal there technology. Nanosonics has taken a strategic position in the protection of its methodologies of disinfections and sterilisation using aerosols over a wide variety of chemistries. It has also taken significant steps to protect the design and technology of its launched product, Trophon® EPR.

The companies life thus far and key main events

Nanosonics Ltd was founded in 2001 and headquartered in Sydney Australia with offices in the USA (Nanosonics Inc) and Europe (Nanosonics Europe GmbH)

Key events

Here are some of the key events in the Nanosonics’ story so far:

Event	Date
Launch current generation Trophon® EPR - Europe	Nov 2011
Launch current generation Trophon® EPR - Australia & NZ	Sept 2011
Launch current generation Trophon® EPR USA	July 2011
Formed Nanosonics Inc in USA	June 2011
GE becomes Exclusive Distributor in North America	May 2011
Obtain 510(k) FDA Clearance	Feb 2011
Forms Nanosonics Europe GmbH	Aug 2007
Launch first generation - Trophon® EPR (Aus + NZ)	Sept 2009
Obtain TGA Certification	Feb 2009
Obtain CE Mark Certification	April 2008
Initial Public Offering (ASX:NAN)	May 2007
Received ISO 13485 certification	Nov 2006